XSEER PHARMACEUTICALS Trademark

Trademark Overview


On Wednesday, January 31, 2024, a trademark application was filed for XSEER PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the XSEER PHARMACEUTICALS trademark a serial number of 98385105. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, December 17, 2024. This trademark is owned by Xseer Pharmaceuticals. The XSEER PHARMACEUTICALS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of obesity, senescence, male hypogonadism, muscle loss, lack of energy, lack of focus, sexual dysfunction, hormone-based disease or disorder; Pharmaceutical preparations for hormone replacement therapy, weight management therapy, antioxidant therapy, intravenous administration therapy for treating or preventing obesity, senescence, male hypogonadism, muscle loss, lack of energy, lack of focus, sexual dysfunction, hormone-based diseases or disorders, anti-aging therapy
xseer pharmaceuticals

General Information


Serial Number98385105
Word MarkXSEER PHARMACEUTICALS
Filing DateWednesday, January 31, 2024
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, December 17, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, December 17, 2024

Trademark Statements


Description of MarkThe mark consists of the words "XSEER PHARMACEUTICALS" with the word "XSEER" shown above the word "PHARMACEUTICALS" and a shield design to the left of the words "XSEER PHARMACEUTICALS" and having four panels with the upper left panel containing a design of three connected hexagons, the upper right panel containing a design of a microscope, the lower left panel containing a design for a DNA molecule and the lower right panel containing a design of a syringe and bottle.
Goods and ServicesPharmaceutical preparations for the treatment and prevention of obesity, senescence, male hypogonadism, muscle loss, lack of energy, lack of focus, sexual dysfunction, hormone-based disease or disorder; Pharmaceutical preparations for hormone replacement therapy, weight management therapy, antioxidant therapy, intravenous administration therapy for treating or preventing obesity, senescence, male hypogonadism, muscle loss, lack of energy, lack of focus, sexual dysfunction, hormone-based diseases or disorders, anti-aging therapy
Indication of Colors claimedColor is not claimed as a feature of the mark.
NOT AVAILABLEPHARMACEUTICALS

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, January 31, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameXseer Pharmaceuticals
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLos Angeles, CA 90025

Party NameXseer Pharmaceuticals
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLos Angeles, CA 90025

Trademark Events


Event DateEvent Description
Wednesday, January 31, 2024NEW APPLICATION ENTERED
Saturday, June 15, 2024NOTICE OF DESIGN SEARCH CODE E-MAILED
Saturday, June 15, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, August 26, 2024ASSIGNED TO EXAMINER
Monday, August 26, 2024NON-FINAL ACTION E-MAILED
Monday, August 26, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, August 26, 2024NON-FINAL ACTION WRITTEN
Thursday, November 21, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, November 21, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, November 21, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, November 22, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 11, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 17, 2024PUBLISHED FOR OPPOSITION
Tuesday, December 17, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED